Which of the following describes acute migraine treatment options?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which of the following describes acute migraine treatment options?

Acute migraine relief relies on drugs that act through several different, non-opioid mechanisms to stop the attack quickly. Non-opioid analgesics like NSAIDs reduce prostaglandin-mediated inflammation and pain, and they’re often effective as first-line relief. Adding caffeine-containing products can boost analgesic effect by providing mild vasoconstriction and enhancing pain relief, which is why combination products are commonly used. Serotonin receptor agonists, known as triptans, are central to acute treatment because they constrict cranial blood vessels and inhibit the release of inflammatory neuropeptides, directly targeting the pathways that drive migraine pain. Blocking the CGRP pathway with antagonists helps prevent the vasodilation and nociceptive signaling that underlies an acute attack, offering another mechanism-based option. Ergot derivatives also have a role by causing vasoconstriction to abort migraines, though they come with more safety concerns and are used less frequently today. Opioids are generally avoided due to dependence risk and potential for rebound headaches, and steroids or antihistamines are not standard first-line options for acute migraine. So the best description of acute migraine treatment options includes non-opioid analgesics, caffeine-containing analgesics, serot onin receptor agonists, CGRP-pathway antagonists, and ergotamines, recognizing that CGRP-targeting therapies are better described as CGRP antagonists rather than agonists in modern practice.

Acute migraine relief relies on drugs that act through several different, non-opioid mechanisms to stop the attack quickly. Non-opioid analgesics like NSAIDs reduce prostaglandin-mediated inflammation and pain, and they’re often effective as first-line relief. Adding caffeine-containing products can boost analgesic effect by providing mild vasoconstriction and enhancing pain relief, which is why combination products are commonly used. Serotonin receptor agonists, known as triptans, are central to acute treatment because they constrict cranial blood vessels and inhibit the release of inflammatory neuropeptides, directly targeting the pathways that drive migraine pain. Blocking the CGRP pathway with antagonists helps prevent the vasodilation and nociceptive signaling that underlies an acute attack, offering another mechanism-based option. Ergot derivatives also have a role by causing vasoconstriction to abort migraines, though they come with more safety concerns and are used less frequently today. Opioids are generally avoided due to dependence risk and potential for rebound headaches, and steroids or antihistamines are not standard first-line options for acute migraine.

So the best description of acute migraine treatment options includes non-opioid analgesics, caffeine-containing analgesics, serot onin receptor agonists, CGRP-pathway antagonists, and ergotamines, recognizing that CGRP-targeting therapies are better described as CGRP antagonists rather than agonists in modern practice.

More practice questions